Adagrasib (KRAZATI™) is an orally available, potent, irreversible, small molecule inhibitor of
KRAS G12C mutant isoform being developed by Mirati Therapeutics for the treatment of …

Circular RNAs (circRNAs) are a class of covalently closed, endogenous ncRNAs. Most
circRNAs are derived from exonic or intronic sequences by precursor RNA back-splicing …

Summary KRAS G12D is the most frequently mutated oncogenic KRAS subtype in solid
tumors and remains undruggable in clinical settings. Here, we developed a high affinity …

Kirsten rat sarcoma viral (KRAS) oncogene is the most commonly mutated isoform of RAS,
accounting for 85% of RAS-driven human cancers. KRAS functioning as a signaling hub …

The RAS gene, also known as the mouse sarcoma virus, includes three genes (KRAS,
HRAS, and NRAS) that are associated with human tumors. Among them, KRAS has the …

Colorectal cancer (CRC) is a heterogeneous disease with a myriad of alterations at the
cellular and molecular levels. Kristen rat sarcoma (KRAS) mutations occur in up to 40% of …

Oncogenic driver mutations have implications that extend beyond cancer cells themselves.
Aberrant tumour cell signalling has various effects on the tumour microenvironment and anti …

AMG510, as the first approved inhibitor for KRASG12C mutation, has shown promising
efficacy in nonsmall-cell lung cancer and colorectal cancer harboring KRASG12C mutation …

KRAS gene mutation is widespread in tumors and plays an important role in various
malignancies. Targeting KRAS mutations is regarded as the “holy grail” of targeted cancer …

The RASopathies are a group of clinically defined developmental syndromes caused by
germline variants of the RAS/mitogen‐activated protein (MAPK) cascade. The prototypic …